IMCD has finally broken out of its falling wedge pattern. The key question now is whether the stock will retest the €91.8 zone to confirm the breakout before launching into a stronger upward move.
At roughly 14.5x expected 2026 earnings, the valuation still fails to capture IMCD’s long-term structural strength. While near-term conditions remain challenging, stabilization in chemical end markets should unlock the company’s advantages in scale, product breadth, and financial flexibility.
Current growth is muted, which the market continues to penalize. Short interest has edged up to about 4.3% of shares, though still at moderate levels. Meanwhile, long-term investors such as Burgundy Asset Management and EdgePoint Investment have recently built positions—signaling renewed confidence.
Patience is being tested, but for those looking beyond 2025, IMCD stands out as a strong compounder temporarily in pause mode. The Strong Buy rating remains, with a €135 target price implying 52% upside.
At roughly 14.5x expected 2026 earnings, the valuation still fails to capture IMCD’s long-term structural strength. While near-term conditions remain challenging, stabilization in chemical end markets should unlock the company’s advantages in scale, product breadth, and financial flexibility.
Current growth is muted, which the market continues to penalize. Short interest has edged up to about 4.3% of shares, though still at moderate levels. Meanwhile, long-term investors such as Burgundy Asset Management and EdgePoint Investment have recently built positions—signaling renewed confidence.
Patience is being tested, but for those looking beyond 2025, IMCD stands out as a strong compounder temporarily in pause mode. The Strong Buy rating remains, with a €135 target price implying 52% upside.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.